The neuropharmacology of (-)-Stepholidine and its potential applications

Current Neuropharmacology

Volumn 5, Issue 4, 2007, Pages 289-294

  Yang, Kechun ^a,b   Jin, Guozhang ^b   Wu, Jie ^a  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Dopamine D1 receptor; Dopamine D2 receptor; Parkinson's disease; Schizophrenia; Stepholidine

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; ATYPICAL ANTIPSYCHOTIC AGENT; BROMOCRIPTINE; BUTYROPHENONE DERIVATIVE; CALCIUM CHANNEL; CARBIDOPA; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; LEVODOPA; NATURAL PRODUCT; NEUROLEPTIC AGENT; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; SPIPERONE; STEPHOLIDINE;

ANTIHYPERTENSIVE ACTIVITY; ANTIOXIDANT ACTIVITY; BINDING AFFINITY; CHINESE HERB; CLINICAL TRIAL; DISEASE COURSE; DOPAMINERGIC SYSTEM; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERTENSION; LOW DRUG DOSE; NERVE CELL DEGENERATION; NERVE DEGENERATION; NEUROMODULATION; NEUROPHARMACOLOGY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; STEPHANIA; STEPHANIA INTERMEDIA; STRUCTURE ACTIVITY RELATION; SUBSTANTIA NIGRA; SYMPTOMATOLOGY;

EID: 37249053312     PISSN: 1570159X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157015907782793649     Document Type: Review

References (90)

1. Abi-Dargham, A., Moore, H. (2003) Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist, 9, 404-416.
2. Adams, J.D., Jr., Odunze, I.N. (1991) Oxygen free radicals and Parkinson's disease. Free Radic. Biol. Med., 10, 161-169.
3. Aizman, O., Brismar, H., Uhlen, P., Zettergren, E., Levey, A.I., Forssberg, H., Greengard, P., Aperia, A. (2000) Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons. Nat. Neurosci., 3, 226-230.
4. Amenta, F., Ricci, A., Rossodivita, I., Avola, R., Tayebati, S.K. (2001) The dopaminergic system in hypertension. Clin. Exp. Hypertens., 23, 15-24.
5. Berendse, H.W.; Galis-de Graaf, Y., Groenewegen, H.J. (1992) Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J. Comp. Neurol., 316, 314-347.
6. Bian, C.F., Duan, S.M., Xing, S.H., Yu, Y.M,, Qin, W., Jin, G.Z., Chen, Y. (1986) Interaction of analgesics and 1-stepholidine. Zhongguo Yao Li Xue Bao, 7, 410-413.
7. Blandini, F., Greenamyre, J.T. (1999) Protective and symptomatic strategies for therapy of Parkinson's disease. Drugs Today (Barc), 35, 473-483.
8. Calabresi, P., Maj, R., Mercuri, N.B., Bernardi, G. (1992) Coactivation of D1 and D2 dopamine receptors is required for long-term synaptic depression in the striatum. Neurosci. Lett., 142, 95-99.
9. Castner, S.A., Williams, G.V., Goldman-Rakic, P.S. (2000) Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science, 287, 2020-2022.
10. Chen, L.F., Gan, J.Z., Wang, F.C. (1986) Analgesic and antipyretic, effects of 1-stepholidine without addiction. Acta Pharmacol. Sin., 7, 311-314.
11. Chen, L.F., Gan, J.Z., Wang, F.C., Yang, C.R. (1985) Analgesic, sedative and antispastic effects of 1-stepholidine. Acta Pharmacol. Sin., 6, 156-158.
12. Cheung, P.Y., Barrington, K.J. (1996) Renal dopamine receptors: mechanisms of action and developmental aspects. Cardiovasc. Res., 31, 2-6.
13. Creese, I., Burt, D.R., Snyder, S.H. (1976) Dopamine, receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481-483.
14. Davis, K.L., Kahn, R.S., Ko, G., Davidson, M. (1991) Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry, 148, 1474-1486.
15. Ding, Y.M., Tang, F.M., Yu, L.P., Fu, Y., Zhang, G.Y., Jin, G.Z. (2000) Relevance between striatal expression of Fos, proenkephalin mRNA, prodynorphin mRNA and rotation induced by 1-stepholidine in 6-hydroxydopamine-lesioned rats. Acta Pharmacol. Sin., 21, 885-892.
16. Dong, Z.J., Chen, L.J., Jin, G.Z., Creese, I. (1997) GTP regulation of (-)-stepholidine binding to R(H) of D1 dopamine receptors in calf striatum. Biochem. Pharmacol., 54, 227-232.
17. Dreher, J.K., Jackson, D.M. (1989) Role of D1 and D2 dopamine receptors in mediating locomotor activity elicited from the nucleus accumbens of rats. Brain Res., 487, 267-277.
18. Ellenbroek, B.A., Zhang, X.X., Jin, G.Z. (2006) Effects of (-)stepholidine in animal models for schizophrenia. Acta Pharmacol. Sin., 27, 1111-1118.
19. Fahn, S., Cohen, G. (1992) The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol., 32, 804-812.
20. Fu, Y., Zhu, Z.T., Zhu, X.Z., Jin, G.Z. (2004) Biphasic firing response of nucleus accumbens neurons elicited by THPB-18 and its correlation with DA receptor subtypes. Acta Pharmacol. Sin., 25, 1597-1605.
21. Gerfen, C.R., Keefe, K.A., Gauda, E.B. (1995) D1 and D2 dopamine receptor function in the striatum: coactivation of D1- and D2-dopamine receptors on separate populations of neurons results in potentiated immediate early gene response in D1-containing neurons. J. Neurosci., 15, 8167-8176.
22. Goldberg, L.J., Kohli, J.D. (1983) Peripheral dopamine receptors: a classification based on potency series and specific antagonism. Trends Pharmacol. Sci., 4, 64-66.
23. Gordon, M.S., Steunkel, C.A., Conlin, P.R., Hollenberg, N.K., Williams, G.H. (1989) The role of dopamine in nonmodulating hypertension. J. Clin. Endocrinol. Metab., 69, 426-432.
24. Grondin, R., Bedard, P.J., Britton, D.R., Shiosaki, K. (1997) Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an wine study in parkinsonian levodopa-primed monkeys. Neurology, 49, 421-426.
25. Guo, H., Yu, Y., Xing, L., Jin, G.Z., Zhou, J. (2002) (-)-Stepholidine promotes proliferation and neuronal differentiation of rat embryonic striatal precursor cells in vitro. Neuroreport, 13, 2085-2089.
26. Guo, X., Chen, L.J., Buda, M., Jin, G.Z. (1992) Effects of 1-stepholidine on tyrosine hydroxylase activity in rat corpus striatum. Acta Pharmacol. Sin. 13, 289-292.
27. Hilditch, A., Drew, G.M. (1985) Peripheral dopamine receptor blockade by SCH 23390 and domperidone in vitro. Eur. J. Pharmacol., 116, 171-174.
28. Hu, G., Hu, Y., Jin, G.Z. (1992) Antagonism of 1-stepholidine on D2 receptor-mediated inhibition of synaptosomal adenylate cyclase in rat corpus striatum. Acta Pharmacol. Sin., 13, 104-110.
29. Huang, K.X., Jin, G.Z. (1992) The antagonistic effects of tetrahydroprotoberberines on dopamine receptors: electrophysiological studies, Sci. China B, 35, 688-696.
30. Huang, K.X., Sun, B.C., Gonon, F.G., Jin, G.Z. (1991) Effects of tetrahydroprotoberberines on dopamine release and 3,4-dihydroxyphenylacetic acid level in corpus striatum, measured by in vivo voltametry. Acta Pharmacol. Sin., 12, 32-36.
31. Huang, K.X., Sun, B.C., Jin, G.Z. (1992) (-)-stepholidine: a dopamine receptor antagonist shows agonistic effect on rotational behavior in 6-hydroxydopamine-lesioned rats. Acta Pharmacol. Sin., 13, 17-22.
32. Ilhan, M., Long, J.P. (1975) Inhibition of the sympathetic nervous system by dopamine. Arch Int. Pharmacodyn. Ther., 216, 440.
33. Illes, P., Norenberg, W. (1989) Dopamine inhibits prostaglandin F2 alpha-induced depolarization of rabbit jejunal arteries via activation of DA1-receptors. Naunyn Schmiedebergs Arch Pharmacol., 339, 483-485.
34. Jin, G.Z., Huang, K.X., Sun, B.C. (1992) Dual actions of(-)-stepholidine on dopamine receptor subtypes after substantia nigra lesion. Neurochem. Int., 20 (Suppl.), 175S-178S.
35. Jin, G.Z., Sun, B.C. (1995) Advances in neuropharmacological effects of (-)-stepholidine on dopamine receptors. Adv. Nat. Sci., 5, 55-63.
36. Jin, G.Z., Wang, X.L., Shi, W.X. (1986) Tetrahydroprotoberberine - a new chemical type of antagonist of dapamine receptors. Sci. Sin. (B), 29, 527-534.
37. Jin, G.Z., Zhu, Z.T., Fu, Y. (2002) (-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. Trends Pharmacol. Sci., 23, 4-7.
38. An, X.L., Shasi, Y., Wang, M.J., Chen, L.J., Jin, G.Z. (2000) Tetrahydropratoberberines inhibit lipid peroxidation and scavenge hydroxyl free radicals. Acta Pharmacol. Sin., 21, 477-480.
39. Jose, P.A., Eisner, G.M., Felder, R.A. (1998) Renal dopamine receptors in health and hypertension. Pharmacol. Ther., 80, 149-182.
40. Jose, P.A., Eisner, G.M., Felder, R.A. (1999) Role of dopamine in the pathogenesis of hypertension. Clin. Exp. Pharmacol. Physiol. Suppl., 26, S10-13.
41. Joyce, J.N., Millan, M.J. (2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today, 10, 917-925.
42. Kidd, P.M. (2000) Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern. Med. Rev., 5, 502-529.
43. Kirouac, G.J., Ganguly, P.K. (1993) Up-regulation of dopamine receptors in the brain of the spontaneously hypertensive rat: an autoradiographic analysis. Neuroscience, 52, 135-141.
44. Kita, K., Shiratani, T., Takenouchi, K., Fukuzako, H., Takigawa, M. (1999) Effects of D1 and D2 dopamine receptor antagonists on cocaine-induced self-stimulation and locomotor activity in rats. Eur. Neuropsychopharmacol., 9, 1-7.
45. Langer, S.Z. (1980) Presynaptic regulation of the release of catecholamines. Pharmacol. Rev., 32, 337-362.
46. Le, W.D., Zhou, C.D., Zhang, C.G., Liu, D.K., Jin, G.Z. (1989) Clinical study on treatment of dyskinesia by (-)-stepholidine. Clin. Neurol., 22, 335-337.
47. Lee, S.P., So, C.H., Rashid, A.J., Varghese, G., Cheng, R., Lanca, A.J., O'Dowd, B.F., George, S.R. (2004) Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal. J. Biol. Chem., 279, 35671-35678.
48. Lei, S., Orensanz, L.M., Mulvany, M.J., Simonsen, U. (1999) Mechanisms involved in the vasorelaxant effect of (-)-stepholidine in rat mesenteric small arteries. Eur. J. Pharmacol., 365, 193-204.
49. Li, P.K., Chen, L.J., Zhao, H., Jin, G.Z. (1999) Treatment of Parkinson disease with 1-stepholidine (SPD) plus bromocriptine. Chin. J. Integr. Tradit. West Med., 19, 428-429.
50. Li, X.T., Wang, Y.L., Wang, J.X., Yang, S.J. (1995) Effects of tetrahydroprotoberberines on cytosolic free calcium in cultured rat single myocardial cells. Acta Pharm. Sin., 30, 567-572.
51. Linthorst, A.C., De Lang, H., De Jong, W., Versteeg, D.H. (1991) Effect of the dopamine D2 receptor agonist quinpirole on the in vivo release of dopamine in the caudate nucleus of hypertensive rats. Eur. J. Pharmacol., 201, 125-133.
52. Miao, Y.S., Zhang, A.Z., Lin, C., Jiang, M.H., Jin, G.Z. (1991) Effects of 1-stepholidine on isolated rabbit basilar artery, mesenteric artery, and thoracic aorta. Acta Pharmacol. Sin., 12, 260-262.
53. Ogawa, N., Edamatsu, R., Mizukawa, K., Asanuma, M., Kohno, M., Mori, A. (1993) Degeneration of dopaminergic neurons and free radicals. Possible participation of levodopa. Adv. Neurol., 60, 242-250.
54. Ogawa, N., Tanaka, K., Asanuma, M., Kawai, M., Masumizu, T., Kohno, M., Mori, A. (1994) Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res., 657, 207-213.
55. Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., Iyo, M., Tateno, Y., Toru, M. (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature, 385, 634-636.
56. Seeman, P., Lee, T. (1975) Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science, 188, 1217-1219.
57. Seeman, P., Niznik, H.B., Guan, H.C., Booth, G., Ulpian, C. (1989) Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc. Natl. Acad. Sci. U. S. A., 86, 10156-10160.
58. Shen, D.L., Jin, G.Z., He, Y.F., Zhang, Z.D., Sun, Z., Lu, Y.Q., Yang, Z.C. (1991) Effect of (-)-stepholidine on blood pressure and alpha-adrenoceptor agonists, KCl- and CaCl2-evoked contractions of aortic strips. Acta Pharmacol. Sin., 12, 514-518.
59. Shi, L., Wang, Y.X., Xue, A.Q. (1996) Relaxing effects of 1-stepholidine on rat resistance arteries. Acta Pharm. Sin., 31, 492-495.
60. Shi, W.X., Chen, Y., Jin, G.Z. (1984) Effect of 1-stepholidine on rotational behavior in rats. Acta Pharmacol. Sin., 5, 222-225.
61. Sibley, D.R., Monsma, F.J., Jr. (1992) Molecular biology of dopamine receptors. Trends Pharmacol. Sci., 13, 61-69.
62. Sun, B.C., Jin, G.Z. (1992) Characteristics of (-)-stepholidine on the firing activity of substantia nigral dopamine neurons after repeated reserpine treatment. Biol. Signals, 1, 331-338.
63. Sun, B.C., Jin, G.Z. (1992) Effects of (-)-stepholidine on firing activity of dopamine neurons in ventral tegmental area of rats. Acta Pharmacol. Sin., 13, 395-399.
64. Sun, B.C., Zhang, X.X., Jin, G.Z. (1996) (-)-Stepholidine acts as a D1 partial agonist on firing activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine-lesioned rats. Life Sci., 59, 299-306.
65. Svenningsson, P., Fredholm, B.B., Bloch, B., Le Moine, C. (2000) Co-stimulation of D(1)/D(5) and D(2) dopamine receptors leads to an increase in c-fos messenger RNA in cholinergic interneurons and a redistribution of c-fos messenger RNA in striatal projection neurons. Neuroscience, 98, 749-757.
66. Tang, F.M., Ding, Y.M., Chen, Y.T., Sun, Y.F., Wang, R., Zhang, G.Y., Jin, G.Z. (1999) Antagonistic effect of 1-stepholidine on striatal ischemic, injury in rat. Acta Pharmacol. Sin., 20, 1073-1078.
67. Ungerstedt, U. (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol., 5, 107-110.
68. Ungerstedt, U., Arbuthnott, G.W. (1970) Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res., 24, 485-493.
69. Uno, H., Kobayashi, H., Handa, Y., Kabuto, M., Kubota, T. (1999) Alterations of calcium/calmodulin-dependent protein kinase II activity in ischaemia-induced neuronal death and neuronal protection against ischaemia in the gerbil hippocampus. Acta Neurochir. (Wien), 141, 287-294.
70. Vachvanichsanong, P., Sela, S., Sidhu, A. (1996) Absence of DA1/DA2 dopamine receptor interactions in proximal tubules of spontaneously hypertensive rats. Am. J. Physiol., 270, F98-105.
71. Van den Buuse, M., Jones, C.R., Wagner, J. (1992) Brain dopamine D-2 receptor mechanisms in spontaneously hypertensive rats. Brain Res. Bull., 28, 289-297.
72. Waite, L.M., Broe, G.A., Creasey, H., Grayson, D., Edelbrock, D., O'Toole, B. (1996) Neurological signs, aging, and the neurodegenerative syndromes. Arch Neurol., 53, 498-502.
73. Willems, J.L., Buylaert, W.A., Lefebvre, R.A., Bogaert, M.G. (1985) Neuronal dopamine receptors on autonomic ganglia and sympathetic nerves and dopamine receptors in the gastrointestinal system. Pharmacol. Rev., 37, 165-216.
74. Wu, D.C., Xing, X.Z., Wang, W.A. Xie, H., Wang, Y.H., Yin, J.F., Sun, Q.Z., Cong, Z., An, G.Z. (2003) A double-blind comparison trial of I-stepholidine and perphenazine in treatment of schizophrenia. Chin. J. New Drugs Clin. Rem., 22, 155-160.
75. Xiong, Z.L., Sun, Z., Jin, G.Z., Chen, Y. (1987) [Influence of I-stepholidine on blood pressure and its relaition to alpha-adrenoceptors]. Acta Pharmacol. Sin., 8, 497-501.
76. Xu, S.X., Yu, L.P., Han, Y.R., Chen, Y., Jin, G.Z. (1989) Effects of tetrahy-droprotoberberines on dopamine receptor subtypes in brain. Acta Pharmacol. Sin., 10, 104-110.
77. Yang, S., Miao, Y.S., Han, Q., Jiang, M.H., Jin, G.Z. (1993) Effects of (-)-stepholidine and tetrahydroberberine on high potassium-evoked contraction and calcium influx in rat artery. Acta Pharmacol. Sin., 14, 235-237.
78. Yao, L.P., Li, X.X., Yu, P.Y., Xu, J., Asico, L.D., Jose, P.A. (1998) Dopamine D1 receptor and protein kinase C isoforms in spontaneously hypertensive rats. Hypertension, 32, 1049-1053.
79. Yeh, B.K., McNay, J.L., Goldberg, L.I. (1969) Attenuation of dopamine renal and mesenteric vasodilation by haloperidol: evidence for a specific dopamine receptor. J. Pharmacol. Exp. Ther., 168, 303-309.
80. Zhang, L., Zhou, R., Xiang, G. (2005) Stepholidine protects against H2O2 neurotoxicity in rat cortical neurons by activation of Akt. Neurosci. Lett., 383, 328-332.
81. Zhang, W., Zhi, J., Guo, W., Zhao, R., Jin, G. (1998) Effects of I-stepholidine on the peripheral vascular dopamine DA1 and DA2 receptor subtypes. Pharm. Sin. Acta, 33, 721-726.
82. Zhang, X.X., Liu, J., Fu, Y., Hu, G.Y., Jin, G.Z. (1999) Action sites of rotation and unit firing induced by I-stepholidine and DA agonists in basal ganglia of 6-OHDA-lesioned rats. Acta Pharmacol. Sin., 20, 979-986.
83. Zhang, X.X., Zhu, Z.T., Jin, G.Z. (1998) Comparison of (-)-stepholidine and D1 or D2 agonists on unit firing of globus pallidus in 6-hydroxydopaminelesioned rats. Life Sci., 63, 537-544.
84. Zhang, Z.D., Jin, G.Z., Xu, S.X., Yu, L.P., Chen, Y., Jiang, F.Y., Zhang, Y.R., Sun, Z., Ding, Y.L., Bian, C.F., Qin, W. (1986) Effects of I-stepholidine on the central nervous and cardiovascular systems. Acta Pharmacol. Sin., 7, 522-526.
85. Zhang, Z.D., Zhou, C.M., Jin, G.Z., Zhang, X., Yang, L. (1990) Pharmacokinetics and autoradiography of [3H] or [14C]stepholidine. Acta Pharmacol. Sin., 11, 289-292.
86. Zhu, X.Z., Li, X.Y., Liu, J. (2004) Recent pharmacological studies on natural products in China. Eur. J. Pharmacol., 500, 221-230.
87. Zhu, Z.T., Fu, Y., Hu, G.Y., Jin, G.Z. (2000) Electrophysiological study on biphasic firing activity elicited by D(1) agonistic-D(2) antagonistic action of (-)-stepholidine in nucleus accumbens. Acta Physiol. Sin., 52, 123-130.
88. Zhu, Z.T., Fu, Y., Hu, G.Y., Jin, G.Z. (2000) Modulation of medical prefrontal cortical D1 receptors on the excitatory firing activity of nucleus accumbens neurons elicited by (-)-Stepholidine. Life Sci., 67, 1265-1274.
89. Zhu, Z.T., Wu, W.R., Fu, Y., Jin, G.Z. (2000) I-stepholidine facilitates inhibition of mPFC DA receptors on subcortical NAc DA release. Acta Pharmacol. Sin., 21, 663-667.
90. Zou, L.L., Liu, J., Jin, G.Z. (1997) Involvement of receptor reserve in D1 agonistic action of (-)-stepholidine in lesioned nats. Biochem. Pharmacol., 54, 233-240.